JP2019511916A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511916A5
JP2019511916A5 JP2018544786A JP2018544786A JP2019511916A5 JP 2019511916 A5 JP2019511916 A5 JP 2019511916A5 JP 2018544786 A JP2018544786 A JP 2018544786A JP 2018544786 A JP2018544786 A JP 2018544786A JP 2019511916 A5 JP2019511916 A5 JP 2019511916A5
Authority
JP
Japan
Prior art keywords
dux4
composition
associated virus
construct
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018544786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511916A (ja
JP6966463B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/019422 external-priority patent/WO2017147467A1/en
Publication of JP2019511916A publication Critical patent/JP2019511916A/ja
Publication of JP2019511916A5 publication Critical patent/JP2019511916A5/ja
Application granted granted Critical
Publication of JP6966463B2 publication Critical patent/JP6966463B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018544786A 2016-02-26 2017-02-24 組換えウイルス産物及びdux4エクソンスキッピングを誘導するための方法 Active JP6966463B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662300500P 2016-02-26 2016-02-26
US62/300,500 2016-02-26
PCT/US2017/019422 WO2017147467A1 (en) 2016-02-26 2017-02-24 Recombinant virus products and methods for inducing dux4 exon skipping

Publications (3)

Publication Number Publication Date
JP2019511916A JP2019511916A (ja) 2019-05-09
JP2019511916A5 true JP2019511916A5 (cg-RX-API-DMAC7.html) 2020-06-11
JP6966463B2 JP6966463B2 (ja) 2021-11-17

Family

ID=59685610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018544786A Active JP6966463B2 (ja) 2016-02-26 2017-02-24 組換えウイルス産物及びdux4エクソンスキッピングを誘導するための方法

Country Status (5)

Country Link
US (2) US11180755B2 (cg-RX-API-DMAC7.html)
EP (1) EP3420109A4 (cg-RX-API-DMAC7.html)
JP (1) JP6966463B2 (cg-RX-API-DMAC7.html)
AU (2) AU2017222653B2 (cg-RX-API-DMAC7.html)
WO (1) WO2017147467A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019051290A1 (en) * 2017-09-07 2019-03-14 The Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR THE TREATMENT OF FACIO-SCAPULO-HUMERAL DYSTROPHY
JP2022516515A (ja) * 2018-12-31 2022-02-28 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Rna標的化crispr-cas13bを使用するdux4 rna発現停止
JP7627495B2 (ja) * 2019-07-12 2025-02-06 学校法人東海大学 DUX4 pre-mRNAのスプライシングを変化させるアンチセンスオリゴヌクレオチド
CA3203585A1 (en) * 2020-11-30 2022-06-02 Research Institute At Nationwide Children's Hospital Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
JP2024518476A (ja) 2021-05-10 2024-05-01 エントラーダ セラピューティクス,インコーポレイティド mRNAスプライシングを調節するための組成物及び方法
US20230279397A1 (en) 2022-03-04 2023-09-07 Locanabio, Inc. Compositions and methods comprising engineered short nuclear rna (snrna)
WO2026011009A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Compositions and methods for muscle disorders
WO2026030242A1 (en) 2024-07-29 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
DE69433922T2 (de) 1993-11-09 2005-07-28 Medical College Of Ohio, Toledo Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびaavの精製
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
EP1696036B1 (en) 1996-09-06 2010-04-21 The Trustees of The University of Pennsylvania Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
ES2566553T3 (es) 2010-03-17 2016-04-13 Association Institut De Myologie ARNnp U7 modificados para el tratamiento de las enfermedades neuromusculares
EP3118316A1 (en) 2010-09-02 2017-01-18 Université de Mons Agents useful in treating facioscapulohumeral muscular dystrophy
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
CA2842798C (en) 2011-07-25 2021-02-23 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
WO2013120038A2 (en) 2012-02-10 2013-08-15 Regents Of The University Of Minnesota Morpholino targeting dux4 for treating fshd
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
WO2015141521A1 (ja) 2014-03-21 2015-09-24 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及び記録媒体
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法

Similar Documents

Publication Publication Date Title
JP2015517803A5 (cg-RX-API-DMAC7.html)
US20190093091A1 (en) Compositions for eradicating flavivirus infections in subjects
JP2015513897A5 (cg-RX-API-DMAC7.html)
HRP20250932T1 (hr) Dostava mišićno specifičnog mikrodistrofina putem vektora adeno-asociranog virusa za liječenje mišićne distrofije
JP2016538885A5 (cg-RX-API-DMAC7.html)
US20190365862A1 (en) Combination therapies for eradicating flavivirus infections in subjects
JP2018520646A5 (cg-RX-API-DMAC7.html)
JP2014512171A5 (cg-RX-API-DMAC7.html)
RU2020108189A (ru) Композиции и способы лечения бокового амиотрофического склероза (als)
RU2016123086A (ru) Способы и композиции для лечения болезни хантингтона
MX2020003092A (es) Vectores de adn no integrantes para la modificacion genetica de celulas.
HRP20240505T1 (hr) Dostava alfa-sarkoglikana vektorom povezanim s adenovirusom i liječenje mišićne distrofije
JP2021500064A5 (cg-RX-API-DMAC7.html)
JP2015532097A5 (cg-RX-API-DMAC7.html)
WO2007127428A3 (en) Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
JP2016537341A5 (cg-RX-API-DMAC7.html)
JP2016520290A5 (cg-RX-API-DMAC7.html)
JP2015516989A5 (cg-RX-API-DMAC7.html)
Yang et al. Multidrug-resistant Aeromonas veronii recovered from channel catfish (Ictalurus punctatus) in China: prevalence and mechanisms of fluoroquinolone resistance
RU2015155332A (ru) Олигонуклеотидные модуляторы в-клеточной cll/лимфомы 11а (bcl11а) и их применение
JP2012223202A5 (cg-RX-API-DMAC7.html)
JP2017523239A5 (cg-RX-API-DMAC7.html)
Pfankuche et al. Reduced angiogenic gene expression in morbillivirus‐triggered oncolysis in a translational model for histiocytic sarcoma
JP2011521661A5 (cg-RX-API-DMAC7.html)
JP2018509154A5 (cg-RX-API-DMAC7.html)